Abstract
The purpose of this parallel treatment group, double-blind. multicenter study was to lharacterize the pharmacokinetics of nevirapine and lamivudine when coadministered to patients with the HIV-1 infection. This pharmacokinetic interaction study was nested within a larger Phase III clinical trial conducted to characterize the safety and efficacy of coadministered nevirapine and lamivudine. One hundred HIV-1 infected patients with CD4+ lymphocyte counts=200 cells/mm3 and who were on a background of nucleoside (zidovudine [ZDV], didanosine [ddl], zalcitabine [ddC], stavudine [d4T]) therapy were randomly assigned to be treated with either nucleoside+ lamivudine+nevirapine or nucleoside+lamivudine+ placebo. Each patient underwent blood sampling at defined times for the purpose of determining the concentration of nevirapine in plasma and lamivudine in serum under steady-state conditions. Each patient was also monitored closely for concomitant administration of other drugs, including ZDV, ddl, ddC, d4T and cotrimoxazole. The pharmacokinetics of nevirapine and lamivudine were characterized using nonlinear mixed-effects modeling. There were no reported serious adverse events during the 40-day pharmacokinetic study. The results of the modeling analysis revealed that nevirapine had no effect on the pharmacokinetics of lamivudine. Estimates of the apparent clearance for nevirapine (CL/F=3.3 L/hour; 95% confidence interval [Cl] 2.9 to 3.7 L/hour) and lamivudine (CL/F 27.6 L/hour; 95% Cl 22 to 33.2 L/hour) were consistent with the values reported in earlier trials. However, the results also showed that concomitant administration of lamivudine with cotrimoxazole resulted in a 31% reduction in the apparent clearance of lamivudine, resulting in a 43% increase in the average steady-state lamivudine serum concentrations. These results indicate that chronic concurrent administration of cotrimoxazole with lamivudine may significantly affect the steady-state pharmacokinetics of lamivudine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Piscitelli SC, Flexner C, Minor JR, Polis MA. Drug interactions in patients with human immunodeficiency virus. Clin Inf Dis. 1996;23:685–693.
Barry M, Mulchahy F, Merry Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokin. 1999;36:289–304.
Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetics interactions. Clin Pharmacokin. 1997;32:210–258.
Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin hvest Drugs. 1996;5:1183–1199.
Lamson MJ, Cort S, Sabo JP, Keimns JJ. Assessment of nevirapine oral bioavailability in healthy volunteers following oral and intravenous administration. Pharm Res. 1995;12:S-415.
Riska PR, Lamson MJ, MacGregor TR, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Disp. 1999;27:895–901.
Havlir D, Cheeseman SH, McLaughlin MM, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Inf Dis. 1995;171:537–545.
Lamson MJ, Cort S, Sabo JP, MacGregor TR, Keirns JJ. Effects of gender on the single and multiple dose pharmacokinetics of nevirapine. Pharm Res. 1995;12:S-101.
Murphy R, Sommadossi JP, Lamson MJ, Hall DB, Myers MM, Dusek A. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in HIV-1 infected individuals. I Inf Dis. 1999;179:1116–1123.
Van Leeuwen R, Lange JMA, Hussey EK, Donn KH, Hall ST, Harker AJ. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992;6:1471–1475.
Moore KHP, Yuen GJ, Raasch RH, Eron JJ, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharm Ther. 1996;59:550–558.
Johnson MA, Moore KHP, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokin. 1999;36:41–66.
Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+cells per cubic millimeter. N Engl J Med. 1995;333:1662–1669.
Pav JW, Rowland LS, Korpalski DJ. HPLG-UV method for quantitation of nevirapine in biological matrices following solid-phase extraction. J Pharm Biomed Anal. 1999;20:91–98.
Beal SL, Sheiner LB. NONMEM Users Guide, Parts I-VI, Division of Clinical Pharmacology, NONMEM Project Group, University of California at San Francisco, San Francisco, CA, 1979–1992.
Jonsson EN, Karisson MO. Xpose-An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51.
S-PLUS Version 4.5. Data Analysis Products Division, MathSoft Seattle, WA.
Sweeney KR, Hsyu P-H, Statkevick P. Renal disposition and drug interaction screening of (-)-2’-deoxy-3’-thiacytidine (3TC) in the isolated perfused rat kidney. Pharm Res. 1995;12:1958–1963.
Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Disposition. 1999;20:285–291.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published: February 17, 2000
Rights and permissions
About this article
Cite this article
Sabo, J.P., Lamson, M.J., Leitz, G. et al. Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. AAPS PharmSci 2, 1 (2000). https://doi.org/10.1208/ps020101
Received:
Accepted:
Published:
DOI: https://doi.org/10.1208/ps020101